Skip to content

US · DWTX · BIOTECHNOLOGY

Dogwood Therapeutics, Inc. (DWTX) intrinsic value and stock valuation

$1.04as of 2026-11-21 · Mkt cap 3.5M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Dogwood Therapeutics, Inc. DCF and intrinsic value

InvestorsCraft values DWTX with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from DWTX’s statements →

Dogwood Therapeutics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Alpharetta, GA 30009 dwtx.com

How the business is doing

Fiscal 2018–2025, USD

Revenue
$0.00
20182025
Net income
-$-34.26M
20182025
Free cash flow
-$-15.62M
20182025
Total equity
$74.9M+20.1% 5y CAGRd
20182025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2018–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-27.97M-$-12.23M-$-5.45M-$-12.32M-$-15.64M
Net income-$-34.26M-$-12.35M-$-5.3M-$-12.25M-$-15.96M
EPSd-$-4.17M-$-11.99M-$-7.07M-$-27.84M-$-48.36M
Operating cash flow-$-15.62M-$-8.79M-$-4.87M-$-11.47M-$-15.69M
Capital expenditure$0.00$0.00$0.00-$0.00$0.00
Free cash flow-$-15.62M-$-8.79M-$-4.87M-$-11.47M-$-15.69M
Total assets$90.2M$94.3M$4.17M$8.37M$15.8M
Total debt$160K$15.6M$0.00$0.00$0.00
Net debt-$-6.36M$740K-$-3.32M-$-7.03M-$-14.01M
Total equity$74.9M$64.3M$3.81M$7.33M$14.5M
Cash and short-term investments$6.52M$14.9M$3.32M$7.03M$14M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$0.00$0.00$0.00$0.00$0.00
Gross profit$0.00$0.00$0.00$0.00$0.00
Research and development expenses$21.9M$3.53M$1.73M$8.07M$10.8M
Selling, general and administrative expenses$6.1M$8.7M$3.72M$4.25M$4.85M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$28M$12.2M$5.45M$12.3M$15.6M
Cost and expenses$28M$12.2M$5.45M$12.3M$15.6M
Interest income$100K$0.00$150K$70K$10K
Interest expense$0.00$90K$0.00$0.00$0.00
Depreciation and amortization$0.00$10K$0.00$0.00$0.00
Ebitda-$-34.03M-$-12.25M-$-5.3M-$-12.25M-$-15.96M
Operating income-$-27.97M-$-12.23M-$-5.45M-$-12.32M-$-15.64M
Total other income/expenses, net-$-6.07M-$-120K$150K$70K-$-320K
Income before tax-$-34.04M-$-12.35M-$-5.3M-$-12.25M-$-15.96M
Income tax expense$220K-$0.00$0.00$0.00$0.00
Net income-$-34.26M-$-12.35M-$-5.3M-$-12.25M-$-15.96M
Weighted average shares outstanding$8.22M$1.03M$750K$440K$330K
Weighted average diluted shares outstanding$8.22M$1.03M$750K$440K$330K
Balance sheet
20252024202320222021
Cash and short-term investments$6.52M$14.9M$3.32M$7.03M$14M
Net receivables$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$8.43M$16.5M$4.17M$8.37M$15.8M
Property, plant and equipment, net$190K$220K$0.00$0.00$0.00
Goodwill and intangible assets$81.4M$77.5M$0.00$0.00$0.00
Long-term investments$0.00$20K$0.00$0.00$0.00
Total non-current assets$81.7M$77.8M$0.00$0.00$0.00
Total assets$90.2M$94.3M$4.17M$8.37M$15.8M
Accounts payable$760K$1.23M$110K$570K$350K
Short-term debt$60K$100K$0.00$0.00$0.00
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$3.06M$3.18M$360K$1.04M$1.28M
Long-term debt$110K$15.5M$0.00$0.00$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$12.2M$26.9M$0.00$0.00$0.00
Capital lease obligations$160K$200K$0.00$0.00$0.00
Total liabilities$15.3M$30M$360K$1.04M$1.28M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-108.08M-$-73.82M-$-61.47M-$-56.17M-$-43.93M
Accumulated other comprehensive income (loss)-$-590K-$-3.86M$0.00$0.00$0.00
Total equity$74.9M$64.3M$3.81M$7.33M$14.5M
Total investments$0.00$20K$0.00$0.00$0.00
Total debt$160K$15.6M$0.00$0.00$0.00
Net debt-$-6.36M$740K-$-3.32M-$-7.03M-$-14.01M
Cash flow statement
20252024202320222021
Net income-$-34.26M-$-12.35M-$-5.3M-$-12.25M-$-15.96M
Depreciation and amortization$0.00$10K$0.00$0.00$0.00
Stock-based compensation$360K$480K$620K$580K$320K
Change in working capital-$-130K-$-580K-$-190K$200K-$-50K
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-530K$220K-$-460K$220K$270K
Net cash provided by operating activities-$-15.62M-$-8.79M-$-4.87M-$-11.47M-$-15.69M
Investments in property, plant and equipment$0.00$0.00$0.00$0.00$0.00
Acquisitions, net$0.00$3.76M$0.00$0.00$0.00
Net cash used for investing activities$0.00$3.76M$0.00$0.00$0.00
Common stock issued$4.34M$1.38M$1.16M$4.49M$0.00
Common stock repurchased$0.00-$0.00$0.00$0.00-$-300K
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$7.28M$16.7M$1.16M$4.49M-$-100K
Net change in cash-$-8.32M$11.5M-$-3.71M-$-6.98M-$-15.79M
Cash at end of period$6.52M$14.9M$3.32M$7.03M$14M
Operating cash flow-$-15.62M-$-8.79M-$-4.87M-$-11.47M-$-15.69M
Capital expenditure$0.00$0.00$0.00-$0.00$0.00
Free cash flow-$-15.62M-$-8.79M-$-4.87M-$-11.47M-$-15.69M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Dogwood Therapeutics, Inc.

        Dogwood Therapeutics, Inc. is an emerging biotechnology firm dedicated to creating innovative antiviral treatments. Their primary goal is to address illnesses that stem from atypical immune reactions provoked by viral infections. Its leading therapeutic candidate, IMC-1, is a precise fixed-dose combination of famciclovir and celecoxib, engineered to combat fibromyalgia. Additionally, the company is advancing IMC-2, which blends valacyclovir and celecoxib, aiming to alleviate the array of symptoms linked to long COVID, including persistent fatigue, sleep disturbances, cognitive issues, pain, autonomic dysfunction, and anxiety. Previously operating as Virios Therapeutics, Inc., the organization adopted the name Dogwood Therapeutics, Inc. in October 2024. Established in 2012, the company maintains its main office in Alpharetta, Georgia.

        CEO
        Gregory Duncan
        Employees
        8
        Beta
        1.71

        Explore

        Frequently asked questions

        What is the intrinsic value of Dogwood Therapeutics, Inc. (DWTX)?

        InvestorsCraft does not currently publish an intrinsic value for DWTX. How the IC value is calculated.

        Is DWTX undervalued?

        InvestorsCraft does not publish an undervaluation signal for DWTX at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.